Table 3.

Changes in QT indices during treatment phases in the 10 patients

	Baseline (mean (SD))	Placebo (mean(SD))	Amiloride (mean(SD))	Changes between placebo and amiloride
QT dispersion (ms)	65.4 (29.2)	65.7 (25.8)	50.9 (26.1)**†	14.8 (9.6) 95% CI 7.9 to 21.7, p=0.001
QTc dispersion (ms)	68.2 (29.0)	68.3 (24.8)	52.6 (25.3)**†	15.7(10.0) 95% CI 8.6 to 22.9, p=0.001
QTcmax (ms)	442.6 (24.6)	445.0 (26.6)	435.2 (25.7)*†	9.8 (9.1) 95% CI 3.3 to 16.2, p=0.008

*p<0.05 between baseline and amiloride treatment phases; **p<0.001 between baseline and amiloride treatment phases; †p<0.05 between placebo and amiloride treatment phases.

QTc, corrected QT interval.